Terminated PHASE1 INTERVENTIONAL 2-arm NCT05762744

Pharmacogenomics of GLP1 Receptor Agonists

Sponsor: University of Maryland, Baltimore

Interventions Exenatide Injection (before the first FSIGT) Exenatide injection before the second FSIGT)

Updated 4 times since 2023 Last updated: Jun 26, 2025 Started: Jun 1, 2016 Primary completion: Nov 30, 2018 Completion: Oct 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

We concluded that it would not be possible to meet our recruitment targets within the available budget. The study was ended when the funding ended.

Other terminated trials from University of Maryland, Baltimore

See all terminations from University of Maryland, Baltimore

Other Type 2 Diabetes trials with similar outcome

Browse all Type 2 Diabetes trials

Listed as NCT05762744, this PHASE1 trial focuses on Type 2 Diabetes and remains terminated or withdrawn. Sponsored by University of Maryland, Baltimore, it has been updated 4 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Aug 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Aug 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Apr 2023 — Jul 2024 [monthly]

Terminated PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Maryland, Baltimore

Data source: University of Maryland, Baltimore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lancaster, United States